Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The telehealth system provider is going public in an $742m upsized offering that will enable Philips, Allianz, Teva and Takeda to exit.

OSU's kidney dialysis technology provider has added about $36m to close its initial public offering, its shares having more than doubled in price.

Novo Ventures and Sanofi Ventures co-led a series C round for the cancer therapy developer, which builds on work at Amsterdam UMC.

Ghent University-founded rapid diagnostic test developer Antelope DX picked up Whitefund and existing investors to bring its funding total to $16.6m.

The kidney dialysis technology provider has added about $36m to close its initial public offering, it shares having more than doubled in price.

SR One, AbbVie Ventures, Takeda Ventures and Pfizer Ventures all returned having already backed the cancer and inflammatory disease drug developer at series A stage.

The healthcare-focused workplace management software provider hiked its total funding to about $225m as Ascension Ventures reinvested.

Novo Ventures and Sanofi Ventures co-led a series C round for the cancer therapy developer with backing from returning investor MRL Ventures Fund.

GV participated in a round that increased the on-demand healthcare service's overall funding to $107m, with the cash to go to expanding its operations.